Please try another search
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Name | Age | Since | Title |
---|---|---|---|
David P. Meeker | 70 | 2017 | Independent Chairman of the Board |
Dominick C. Colangelo | 60 | 2020 | Independent Director |
Jennifer L. Good | 59 | 2011 | Co-Founder, CEO, President & Director |
Anne M. VanLent | 76 | 2018 | Independent Director |
Edward T. Mathers | 64 | 2017 | Independent Director |
Dawn McGuire | - | 2013 | Member of Clinical Advisory Board |
Michael Thomas Heffernan | 60 | 2017 | Independent Director |
Jeffrey Bernhard | - | 2013 | Member of Clinical Advisory Board |
James V. Cassella | 69 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review